The role of intestinal microbiota in the development of dyslipidemia and cardiovascular disease risk

Authors

DOI:

https://doi.org/10.14739/2310-1210.2024.2.291575

Keywords:

dysbiosis, bile acids, metabolism, metabolites, microbiome, prebiotics, probiotics

Abstract

The aim of the study: to summarize the study results on the interaction between intestinal microbiota and the human body in terms of the risk for dyslipidemia and cardiovascular system diseases.

Material and methods. A descriptive and comparative study was conducted based on the analysis of scientific literature focused on the role of intestinal microbiota in the occurrence of dyslipidemia and the development of cardiovascular diseases. The following research methods were used: search, comparative, analysis of scientific literature, generalization, synthesis.

Results. Gut microbiota plays an important role in maintaining health, and its pathology contributes to the risk for cardiovascular diseases. In some cases, monitoring the intestinal microbiota and the preventive use of pre- and probiotics can reduce the risk for developing cardiovascular system diseases.

Conclusions. It has been found that trimethylamine-N-oxide, a microbiota-dependent metabolite, is the first of many existing bacterial products with the proven role in the development of cardiovascular system diseases.

Author Biography

T. V. Bogoslav, Zaporizhzhia State Medical and Pharmaceutical University, Ukraine

MD, PhD, Associate Professor of the Department of Internal Diseases 1

References

  1. Ascher S, Reinhardt C. The gut microbiota: An emerging risk factor for cardiovascular and cerebrovascular disease. Eur J Immunol. 2018;48(4):564-75. doi: https://doi.org/10.1002/eji.201646879
  2. Fialho A, Fialho A, Kochhar G, Schenone AL, Thota P, McCullough AJ, et al. Association Between Small Intestinal Bacterial Overgrowth by Glucose Breath Test and Coronary Artery Disease. Dig Dis Sci. 2018;63(2):412-21. doi: https://doi.org/10.1007/s10620-017-4828-z
  3. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. Nature. 2011;473(7346):174-80. doi: https://doi.org/10.1038/nature09944
  4. Ahmadmehrabi S, & Tang WHW. Gut microbiome and its role in cardiovascular diseases. Curr Opin Cardiol. 2017;32(6):761-766. https://doi:10.1097/HCO.0000000000000445
  5. Yan Q, Gu Y, Li X, Yang W, Jia L, Chen C, Han X, Huang Y, Zhao L, Li P, Fang Z, Zhou J, Guan X, Ding Y, Wang S, Khan M, Xin Y, Li S, Ma Y. Alterations of the Gut Microbiome in Hypertension. Front Cell Infect Microbiol. 2017;7:381. doi: https://doi.org/10.3389/fcimb.2017.00381
  6. Gózd-Barszczewska A, Kozioł-Montewka M, Barszczewski P, Młodzińska A, Humińska K. Gut microbiome as a biomarker of cardiometabolic disorders. Ann Agric Environ Med. 2017;24(3):416-22. doi: https://doi.org/10.26444/aaem/75456
  7. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027-31. doi: https://doi.org/10.1038/nature05414
  8. Heianza Y, Ma W, Manson JE, Rexrode KM, Qi L. Gut Microbiota Metabolites and Risk of Major Adverse Cardiovascular Disease Events and Death: A Systematic Review and Meta-Analysis of Prospective Studies. J Am Heart Assoc. 2017;6(7):e004947. doi: https://doi.org/10.1161/JAHA.116.004947
  9. Yadav M, Verma MK, Chauhan NS. A review of metabolic potential of human gut microbiome in human nutrition. Arch Microbiol. 2018;200(2):203-17. doi: https://doi.org/10.1007/s00203-017-1459-x
  10. Asano Y, Hiramoto T, Nishino R, Aiba Y, Kimura T, Yoshihara K, et al. Critical role of gut microbiota in the production of biologically active, free catecholamines in the gut lumen of mice. Am J Physiol Gastrointest Liver Physiol. 2012;303(11):G1288-95. doi: https://doi.org/10.1152/ajpgi.00341.2012
  11. Jin M, Qian Z, Yin J, Xu W, Zhou X. The role of intestinal microbiota in cardiovascular disease. J Cell Mol Med. 2019;23(4):2343-50. doi: https://doi.org/10.1111/jcmm.14195
  12. Nowiński A, Ufnal M. Trimethylamine N-oxide: A harmful, protective or diagnostic marker in lifestyle diseases? Nutrition. 2018;46:7-12. doi: https://doi.org/10.1016/j.nut.2017.08.001
  13. Ahmadmehrabi S, Tang WHW. Gut microbiome and its role in cardiovascular diseases. Curr Opin Cardiol. 2017;32(6):761-6. doi: https://doi.org/10.1097/HCO.0000000000000445
  14. Anders HJ, Andersen K, Stecher B. The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney Int. 2013;83(6):1010-6. doi: https://doi.org/10.1038/ki.2012.440
  15. Liu Z, Li J, Liu H, Tang Y, Zhan Q, Lai W, et al. The intestinal microbiota associated with cardiac valve calcification differs from that of coronary artery disease. Atherosclerosis. 2019;284:121-8. doi: https://doi.org/10.1016/j.atherosclerosis.2018.11.038
  16. Moran-Ramos S, López-Contreras BE, Canizales-Quinteros S. Gut Microbiota in Obesity and Metabolic Abnormalities: A Matter of Composition or Functionality? Arch Med Res. 2017;48(8):735-53. doi: https://doi.org/10.1016/j.arcmed.2017.11.003
  17. Fu J, Bonder MJ, Cenit MC, Tigchelaar EF, Maatman A, Dekens JA, et al. The Gut Microbiome Contributes to a Substantial Proportion of the Variation in Blood Lipids. Circ Res. 2015;117(9):817-24. doi: https://doi.org/10.1161/CIRCRESAHA.115.306807
  18. Pluznick JL. Microbial Short-Chain Fatty Acids and Blood Pressure Regulation. Curr Hypertens Rep. 2017;19(4):25. doi: https://doi.org/10.1007/s11906-017-0722-5
  19. Khan MJ, Gerasimidis K, Edwards CA, Shaikh MG. Role of Gut Microbiota in the Aetiology of Obesity: Proposed Mechanisms and Review of the Literature. J Obes. 2016;2016:7353642. doi: https://doi.org/10.1155/2016/7353642
  20. Tang WH, Kitai T, Hazen SL. Gut Microbiota in Cardiovascular Health and Disease. Circ Res. 2017;120(7):1183-96. doi: https://doi.org/10.1161/CIRCRESAHA.117.309715
  21. Kaska L, Sledzinski T, Chomiczewska A, Dettlaff-Pokora A, Swierczynski J. Improved glucose metabolism following bariatric surgery is associated with increased circulating bile acid concentrations and remodeling of the gut microbiome. World J Gastroenterol. 2016;22(39):8698-719. doi: https://doi.org/10.3748/wjg.v22.i39.8698
  22. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55-60. doi: https://doi.org/10.1038/nature11450
  23. Forslund K, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015;528(7581):262-6. doi: https://doi.org/10.1038/nature15766
  24. Xie J, Lu W, Zhong L, Hu Y, Li Q, Ding R, et al. Alterations in gut microbiota of abdominal aortic aneurysm mice. BMC Cardiovasc Disord. 2020;20(1):32. doi: https://doi.org/10.1186/s12872-020-01334-2
  25. Shikata F, Shimada K, Sato H, Ikedo T, Kuwabara A, Furukawa H, et al. Potential Influences of Gut Microbiota on the Formation of Intracranial Aneurysm. Hypertension. 2019;73(2):491-6. doi: https://doi.org/10.1161/HYPERTENSIONAHA.118.11804
  26. Yang S, Li X, Yang F, Zhao R, Pan X, Liang J, et al. Gut Microbiota-Dependent Marker TMAO in Promoting Cardiovascular Disease: Inflammation Mechanism, Clinical Prognostic, and Potential as a Therapeutic Target. Front Pharmacol. 2019;10:1360. doi: https://doi.org/10.3389/fphar.2019.01360
  27. Janeiro MH, Ramírez MJ, Milagro FI, Martínez JA, Solas M. Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target. Nutrients. 2018;10(10):1398. doi: https://doi.org/10.3390/nu10101398
  28. Antony S, Leon MP de. Probiotics and its relationship with the cardiovascular system. In: Probiotics - Current Knowledge and Future Prospects. InTech; 2018. https://doi.org/10.5772/intechopen.75077
  29. Yoshida N, Emoto T, Yamashita T, Watanabe H, Hayashi T, Tabata T, et al. Bacteroides vulgatus and Bacteroides dorei Reduce Gut Microbial Lipopolysaccharide Production and Inhibit Atherosclerosis. Circulation. 2018;138(22):2486-98. doi: https://doi.org/10.1161/CIRCULATIONAHA.118.033714
  30. Zhu W, Gregory JC, Org E, Buffa JA, Gupta N, Wang Z, et al. Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk. Cell. 2016;165(1):111-24. doi: https://doi.org/10.1016/j.cell.2016.02.011
  31. Richards EM, Pepine CJ, Raizada MK, Kim S. The Gut, Its Microbiome, and Hypertension. Curr Hypertens Rep. 2017;19(4):36. doi: https://doi.org/10.1007/s11906-017-0734-1
  32. Robles-Vera I, Toral M, de la Visitación N, Sánchez M, Gómez-Guzmán M, Romero M, et al. Probiotics Prevent Dysbiosis and the Rise in Blood Pressure in Genetic Hypertension: Role of Short-Chain Fatty Acids. Mol Nutr Food Res. 2020;64(6):e1900616. doi: https://doi.org/10.1002/mnfr.201900616
  33. Katsimichas T, Antonopoulos AS, Katsimichas A, Ohtani T, Sakata Y, Tousoulis D. The intestinal microbiota and cardiovascular disease. Cardiovasc Res. 2019;115(10):1471-86. doi: https://doi.org/10.1093/cvr/cvz135
  34. Ganesh BP, Nelson JW, Eskew JR, Ganesan A, Ajami NJ, Petrosino JF, et al. Prebiotics, Probiotics, and Acetate Supplementation Prevent Hypertension in a Model of Obstructive Sleep Apnea. Hypertension. 2018;72(5):1141-50. doi: https://doi.org/10.1161/HYPERTENSIONAHA.118.11695
  35. Yang T, Santisteban MM, Rodriguez V, Li E, Ahmari N, Carvajal JM, et al. Gut dysbiosis is linked to hypertension. Hypertension. 2015;65(6):1331-40. doi: https://doi.org/10.1161/HYPERTENSIONAHA.115.05315
  36. Vasquez EC, Pereira TMC, Peotta VA, Baldo MP, Campos-Toimil M. Probiotics as Beneficial Dietary Supplements to Prevent and Treat Cardiovascular Diseases: Uncovering Their Impact on Oxidative Stress. Oxid Med Cell Longev. 2019;2019:3086270. doi: https://doi.org/10.1155/2019/3086270
  37. Kitai T, Tang WH. Gut microbiota in cardiovascular disease and heart failure. Clin Sci (Lond). 2018;132(1):85-91. doi: https://doi.org/10.1042/CS20171090
  38. Zhu Q, Gao R, Zhang Y, Pan D, Zhu Y, Zhang X, et al. Dysbiosis signatures of gut microbiota in coronary artery disease. Physiol Genomics. 2018;50(10):893-903. doi: https://doi.org/10.1152/physiolgenomics.00070.2018
  39. Amin AM, Mostafa H, Arif NH, Abdul Kader MA, Kah Hay Y. Metabolomics profiling and pathway analysis of human plasma and urine reveal further insights into the multifactorial nature of coronary artery disease. Clin Chim Acta. 2019;493:112-22. doi: https://doi.org/10.1016/j.cca.2019.02.030
  40. Liu H, Chen X, Hu X, Niu H, Tian R, Wang H, et al. Alterations in the gut microbiome and metabolism with coronary artery disease severity. Microbiome. 2019;7(1):68. doi: https://doi.org/10.1186/s40168-019-0683-9
  41. Malik M, Suboc TM, Tyagi S, Salzman N, Wang J, Ying R, et al. Lactobacillus plantarum 299v Supplementation Improves Vascular Endothelial Function and Reduces Inflammatory Biomarkers in Men With Stable Coronary Artery Disease. Circ Res. 2018;123(9):1091-102. doi: https://doi.org/10.1161/CIRCRESAHA.118.313565
  42. Horvath A, Leber B, Feldbacher N, Tripolt N, Rainer F, Blesl A, et al. Effects of a multispecies synbiotic on glucose metabolism, lipid marker, gut microbiome composition, gut permeability, and quality of life in diabesity: a randomized, double-blind, placebo-controlled pilot study. Eur J Nutr. 2020;59(7):2969-83. doi: https://doi.org/10.1007/s00394-019-02135-w
  43. Tang TW, Chen HC, Chen CY, Yen CY, Lin CJ, Prajnamitra RP, et al. Loss of Gut Microbiota Alters Immune System Composition and Cripples Postinfarction Cardiac Repair. Circulation. 2019;139(5):647-59. doi: https://doi.org/10.1161/CIRCULATIONAHA.118.035235
  44. Lam V, Su J, Koprowski S, Hsu A, Tweddell JS, Rafiee P, et al. Intestinal microbiota determine severity of myocardial infarction in rats. FASEB J. 2012;26(4):1727-35. doi: https://doi.org/10.1096/fj.11-197921
  45. Mayerhofer CC, Kummen M, Holm K, Broch K, Awoyemi A, Vestad B, et al. Low fibre intake is associated with gut microbiota alterations in chronic heart failure. ESC Heart Fail. 2020;7(2):456-66. doi: https://doi.org/10.1002/ehf2.12596
  46. Kitai T, Kirsop J, Tang WH. Exploring the Microbiome in Heart Failure. Curr Heart Fail Rep. 2016;13(2):103-9. doi: https://doi.org/10.1007/s11897-016-0285-9
  47. Tang WHW, Li DY, Hazen SL. Dietary metabolism, the gut microbiome, and heart failure. Nat Rev Cardiol. 2019;16(3):137-54. doi: https://doi.org/10.1038/s41569-018-0108-7
  48. Liu Z, Liu HY, Zhou H, Zhan Q, Lai W, Zeng Q, et al. Moderate-Intensity Exercise Affects Gut Microbiome Composition and Influences Cardiac Function in Myocardial Infarction Mice. Front Microbiol. 2017;8:1687. doi: https://doi.org/10.3389/fmicb.2017.01687
  49. Lataro RM, Imori PF, Santos ES, Silva LE, Duarte RT, Silva CA, et al. Heart failure developed after myocardial infarction does not affect gut microbiota composition in the rat. Am J Physiol Gastrointest Liver Physiol. 2019;317(3):G342-8. doi: https://doi.org/10.1152/ajpgi.00018.2019

Downloads

Published

2024-03-29

How to Cite

1.
Bogoslav TV. The role of intestinal microbiota in the development of dyslipidemia and cardiovascular disease risk. Zaporozhye Medical Journal [Internet]. 2024Mar.29 [cited 2026May14];26(2):149-53. Available from: https://zmj.zsmu.edu.ua/article/view/291575

Issue

Vol. 26 No. 2 (2024)

Section

Review

License

Authors who publish with this journal agree to the following terms:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.  Лицензия Creative Commons